Detail akcie Dr Reddy Labs Depository Receipt online

Business Summary: Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Financial Summary: BRIEF: For the nine months ended 31 December 2025, Dr Reddy's Laboratories Ltd (ADR) revenues increased 8% to RS260.77B. Net income increased less than 1% to RS40.65B. Revenues reflect Global Generics segment increase of 9% to RS233.23B, Pharmaceutical Services and Active Ingredients segment increase of 6% to RS25.65B, Other segment increase of 28% to RS85.62B, Russia segment increase of 36% to RS26.39B.